Opinion

Video

Looking Beyond Type 2 Inflammation in Atopic Dermatitis

Author(s):

Christopher G. Bunick, MD, PhD,Lindsay S. Ackerman, MD, FAAD

Focusing on the complex pathophysiology of atopic dermatitis, Lindsay S. Ackerman, MD, FAAD, discusses the importance of looking beyond type 2 inflammation while treating patients.

Video content above is prompted by the following:

  • With better understanding of the pathophysiology of atopic dermatitis, how important is to look beyond type 2 inflammation?
Related Videos
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
Discussing FDA Approval of Tapinarof Cream for Atopic Dermatitis, with John Browning, MD
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
Related Content
Study Highlights Interim Results on Abrocitinib for Adolescents, Adults with Atopic Dermatitis
December 19th 2024

Study Highlights Interim Results on Abrocitinib for Adolescents, Adults with Atopic Dermatitis

Tim Smith
Advances in Pediatric Eczema Highlight 2022
December 21st 2022

Advances in Pediatric Eczema Highlight 2022

Kevin Kunzmann
Coco Dekkers, PhD candidate I Credit: LinkedIn
December 18th 2024

Tralokinumab Effectively Treats Moderate-to-Severe Atopic Dermatitis: Real-World Data

Chelsie Derman
How Pegloticase Plus Methotrexate is Breaking Ground in Gout Care
July 12th 2022

How Pegloticase Plus Methotrexate is Breaking Ground in Gout Care

Armand Butera
Christopher G. Youn, MD Candidate I Credit: Stanford Biosciences
December 18th 2024

Parents of Children with Atopic Dermatitis Often Sleep Less Than 7 Hours

Chelsie Derman
FDA Receives sNDA for Roflumilast Cream Treatment of Children with Atopic Dermatitis
December 16th 2024

FDA Receives sNDA for Roflumilast Cream Treatment of Children with Atopic Dermatitis

Tim Smith
© 2024 MJH Life Sciences

All rights reserved.